

Product Information

CompoZr® Disease Model Cell Lines MCF10A Cells CDC25B -/-

Catalog Number **CLLS1060**

Storage Temperature -196 °C (liquid nitrogen)

Product Description

CompoZr® zinc finger nuclease (ZFN) technology is a fast and reliable way to manipulate the genome in a targeted fashion. ZFNs are synthetic proteins engineered to bind DNA at a sequence-specific location and create a double strand break (www.compozrzfn.com). The cell's natural machinery repairs the break in one of two ways: non-homologous end joining or homologous recombination. The non-homologous end joining pathway resulted in deletions at the CDC25B locus (see Figure 1). Single cell knockout clones were isolated and followed for more than twenty passages to establish stable cell lines.

While the targeted gene in this cell line is diploid, ZFN-mediated gene knockout technology is not limited to diploid targets, allowing the researcher to pursue many of the polyploid cell lines often characteristic of cancer. Modified cell lines provide the basis for the development of various assays for compound screening. Here, the target gene and resulting protein, CDC25B isoform 2, are disrupted, in contrast to cell lines expressing fully functional wild type CDC25B.

Cell Division Cycle 25 Homolog B (CDC25B) is a member of the CDC25 family of phosphatases, which has three isoforms in human cells: CDC25A, CDC25B and CDC25C. CDC25B activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G₁ phases of the cell cycle, and moves to the cytoplasm during S and G₂.

CDC25 phosphatases regulate key transitions between cell cycle phases during normal cell division and, in the event of DNA damage, they are key targets of the checkpoint machinery that ensures genetic stability. CDC25 phosphatases are functionally inactivated or degraded to stop cell-cycle progression. CDC25B activity is required for checkpoint recovery.

CDC25A and CDC25B overexpression is frequently found in many cancers and are often associated with high-grade tumors and poor prognosis.¹⁻¹⁰ Recently, specific isoforms of the CDC25B protein have been identified associated with recovery from the G₁/M checkpoint and may prove to play a more salient role in carcinogenesis.¹¹

For further information and to download sequence of modified locus, go to the website:
www.wherebiobegins.com/biocells

Figure 1.

Creation of CDC25B Knockout in MCF10A Cells

Site-specific deletion at the CDC25B Locus in MCF10A cell line, Alleles 1 and 2 – 1 bp deletion:

```
ATGGAGGTGCCCCAGCCGGAGCCCGCGCCCAGGCT
CGGCTCTCAGTCCAGCAGGCGTGTGCGGTGGCGC
CCAGCGTCCGGGCCACCTCCCGGGCCTCCTGCTG
GGATCTCATGGCCTCCTGGGGTCCCCGGTGCGGG
CGGCCGCTTCCTCGCGGTCACTccctcACCCAGA
CCATGCACGACCTCGCCGGGCTCGGCAGGTAGGA
CACCCCAAGGAGGCTGCATATGGGGTGAGAGGC
TAGGTCTGGAGTCCTGGGCCTCCTGGAGAACTGG
GCATGGTAGTCGAATCCAGGAGGTGGAGTCCGGG
GAGGCATCCTGAGCAGTGGAGAGGTACGCCCTTG
TTCCCTCCTAGGGGCCAG
```

Schematic of the genomic sequence at the target region (intronic region in native genome following exon 1; results in deletion in exon 1 of isoforms 1, 2, and 3 of coding mRNA, resulting in proteins of 580, 566, and 539 amino acids, respectively, per UCSC Genome Bioinformatics database) recognized by the ZFN pair; the resulting deletion, and the CEL-I primer sequences:

CEL-I Primers - **Bolded and underlined**
ZFN binding site - **UPPER CASE, BOLDED RED**
ZFN cut site - **lower case red**
Deletion - **yellow highlighted**

Genotype: del 1/del 1 (homozygous)

Components

MCF10A mutant cell line with CDC25B gene knocked out 1 vial
Catalog No. CLL1060

Parental mammary epithelial cell line 1 vial
(ATCC® Catalog No. CRL-10317™)
Catalog No. CLL1040

Cell Line Description

1 vial of modified MCF10a cells contains $\sim 2 \times 10^6$ cells.

Organism: *Homo sapiens* (human)

Tissue: mammary gland; breast

Age: 36 years

Gender: Female

Ethnicity: Caucasian

Morphology: Epithelial

Growth properties: Adherent

DNA profile

Short Tandem Repeat (STR) analysis:

Amelogenin: X

CSF1PO: 10,12

D13S317: 8,9

D16S539: 11,12

D5S818: 10,13

D7S820: 10,11

THO1: 8,9,3

TPOX: 9,11

vWA: 15,17

Parental Cell Line: ATCC Catalog No. CRL-10317

Note: Please see CRL-10317 product datasheet from ATCC for additional information about the origin of these cell lines. Cytogenetic information is based on initial seed stock at Sigma Life Science. Cytogenetic instability has been reported in the literature for some cell lines.

Complete Medium: Dulbecco's Modified Eagle's Medium (DMEM)/Ham's Nutrient Mixture F12 (1:1) with 2.5 mM L-glutamine, 5% horse serum, 10 µg/mL human insulin, 0.5 µg/mL hydrocortisone, 10 ng/mL EGF, and 100 ng/mL cholera toxin. This medium is formulated for use with a 5% CO₂ in air atmosphere.

Medium Components:

Cholera Toxin from *V. cholerae*,

Catalog Number C8052

DMEM/F12, Catalog Number 51448C

Insulin Solution, Catalog Number I9278

Epidermal Growth Factor, Catalog Number E9644

50 µM Hydrocortisone Solution,

Catalog Number H6909

Horse Serum, Catalog Number H1270

The cryoprotectant medium used is 1× Cell Freezing Medium-DMSO, Catalog No. C6164.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Biosafety Level: 1

This cell line is not known to harbor an agent known to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. The parental cell line, MCF10A, was obtained from ATCC. All animal products used in the preparation of the knockout line and maintenance of both, parental and knockout clone, have been screened negative by 9CFR for adventitious viral agents. Cell lines derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. Appropriate safety procedures are recommended to be used when handling all cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures have been published.¹²⁻¹⁵

Preparation Instructions

Complete Medium: To make the complete growth medium combine the following:

1 L of DMEM/F12 (Catalog Number 51448C)
50 mL of horse serum (Catalog Number H1270)
29 mL of 50 μ M Hydrocortisone Solution (Catalog Number H6909)
1.08 mL of Insulin Solution (Catalog Number I9278)
108 μ L of Cholera toxin solution (1 mg/mL), prepared by dissolving Catalog Number C8052 in sterile water. Store solution at 2–8 °C.
10.8 μ L of EGF solution (1 mg/mL), prepared by dissolving Catalog Number E9644 in 10 mM acetic acid, followed by 0.2 μ m filtration. Store the solution in aliquots at –20 °C.

Storage/Stability

Upon receiving a shipment of frozen cells it is important the end user gives the shipment attention without delay. To ensure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at –70 °C. Storage at –70 °C will result in loss of viability.

Precaution: It is recommended that protective gloves and clothing always be used, and a full face mask always be worn when handling frozen vials. It is **important to note that some vials leak when submersed in liquid nitrogen** and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to the gas phase may result in the rapid expansion of the vessel, potentially blowing off its cap with dangerous force creating flying debris.

At the time a cell line is ordered, end users should also consider the culture conditions for the new cell line and make sure the appropriate medium will be available when the cells arrive.

Procedure

Thawing of Frozen Cells

1. Thaw the vial by gentle agitation in a 37 °C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (~2 minutes).
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
3. Transfer the vial contents to a centrifuge tube containing 9.0 mL of Complete Medium and spin at ~125 \times g for 5–7 minutes.
4. Resuspend cell pellet with the Complete Medium and dispense into a 25 cm² or a 75 cm² culture flask. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested, prior to the addition of the vial contents, the culture vessel containing the Complete Medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0–7.6) and temperature (37 °C).
5. Incubate the culture at 37 °C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended for the Complete Medium.

Subculturing Procedure

Volumes used in this procedure are for a 75 cm² flask; proportionally reduce or increase volume of dissociation medium for culture vessels of other sizes.

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with Trypsin-EDTA solution (Catalog No. T3924).
3. Add 2.0–3.0 mL of Trypsin-EDTA solution to the flask and incubate at 37 °C for 15 minutes. This should remove the cells from the cultureware and yield single cells.
4. When cells are detached, add 6.0–8.0 mL of Complete Medium and aspirate cells by gentle pipetting.
5. Add appropriate aliquots of the cell suspension into new culture vessels.
Subcultivation Ratio: 1:3 to 1:6
6. Incubate cultures at 37 °C.

Note: MCF10A cells require longer time for trypsin digestion than what is typical. More information on enzymatic dissociation and subculturing of cell lines is available in the literature.¹⁶

References

1. Boutros, R. et al., CDC25 phosphatases in cancer cells: key players? Good targets? *Nat. Rev. Cancer*, **7** (7), 495-507 (2007).
2. Kiyokawa, H., and Dipankar, R., *In vivo* roles of CDC25 phosphatases: Biological insight into the anti-cancer therapeutic targets. *Anticancer Agents Med. Chem.*, **8** (8), 832–836 (2008).
3. Ito, Y. et al., Expression of cdc25A and cdc25B phosphatase in breast carcinoma. *Breast Cancer*, **11** (3), 295-300 (2004).
4. Takemasa, I. et al., Overexpression of CDC25B phosphatase as a novel Marker of poor prognosis of human colorectal carcinoma. *Cancer Res.*, **60**, 3043-3050 (2000).
5. Wang, Z. et al., Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. *BMC Cancer*, **10**, 233 (2010).
6. Guo, J. et al., Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. *Oncogene*, **23** (1), 71-81 (2004).
7. Ito, Y. et al., Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. *Cancer Lett.*, **229** (2), 291-7 (2005).
8. Sasaki, H. et al., Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. *Cancer Lett.*, **173** (2), 187-92 (2001).
9. Nakabayashi, H. et al., Prognostic significance of CDC25B expression in gliomas. *J. Clin. Pathol.*, **59**, 725–728 (2006).
10. Gasparotto, D. et al., Overexpression of CDC25A and CDC25B in head and neck Cancers. *Cancer Res.*, **57**, 2366-2368 (1997).
11. Jullien, D. et al., Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2/M checkpoint recovery. *Canc. Res.*, **71**, 1968 (2011).
12. Centers for Disease Control (1999), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 4th Edition U.S. Government Printing Office Washington D.C. Entire text is available online at www.cdc.gov/od/ohs/biosfty/bmb14/bmb14toc.htm
13. Fleming, D.O. et al., (1995) *Laboratory Safety: Principles and Practice*. Second edition, ASM press, Washington, DC.
14. Hay, R.J. et al., eds. (1992), *ATCC Quality Control Methods for Cell Lines*. 2nd edition, Published by ATCC.
15. Caputo, J.L., Biosafety procedures in cell culture. *J. Tissue Culture Methods*, **11**, 223-227 (1988).
16. Freshney, R.I., Chapter 10 in *Culture of Animal Cells, a manual of Basic Technique* by, 3rd edition, published by Alan R. Liss, (NY, NY: 1994).

Additional product and technical information can be obtained from the catalog references and the Sigma Life Science Website (www.wherebiobegins.com/biocells).

CompoZr is a registered trademark of Sigma-Aldrich® Biotechnology LP and Sigma-Aldrich Co. ATCC is a registered trademark of American Type Culture Collection. CRL-10317 is a trademark of American Type Culture Collection.

Please see the enclosed Label License Agreement (LLA) for further details regarding the use of this product. The LLA is also available on our website at www.wherebiobegins.com/biocells

These cells are distributed for research purposes only. Sigma Life Science requires that individuals contemplating commercial use of any cell line first contact us to negotiate an agreement. Third party distribution of this cell line is prohibited.

GW,ADM,MAM 06/11-1

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.